Form 8-K - Current report:
SEC Accession No. 0001326190-25-000024
Filing Date
2025-03-13
Accepted
2025-03-13 16:03:28
Documents
14
Period of Report
2025-03-13
Items
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K alt-20250313x8k.htm   iXBRL 8-K 39115
  Complete submission text file 0001326190-25-000024.txt   178633

Data Files

Seq Description Document Type Size
2 EX-101.SCH alt-20250313.xsd EX-101.SCH 3267
3 EX-101.LAB alt-20250313_lab.xml EX-101.LAB 18712
4 EX-101.PRE alt-20250313_pre.xml EX-101.PRE 12845
16 EXTRACTED XBRL INSTANCE DOCUMENT alt-20250313x8k_htm.xml XML 4868
Mailing Address 910 CLOPPER ROAD SUITE 201S GAITHERSBURG MD 20878
Business Address 910 CLOPPER ROAD SUITE 201S GAITHERSBURG MD 20878 2406541450
Altimmune, Inc. (Filer) CIK: 0001326190 (see all company filings)

EIN.: 202726770 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-32587 | Film No.: 25735664
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)